Source: http://feedproxy.google.com/~r/RolePlayGateway/~3/ub0SpZV0ue0/viewtopic.php
beyonce troy polamalu james harrison james harrison falcons giants game norman borlaug
Monday, March 5, 2012
Need Drummer for Band Roleplay
One of the drummers in the band RP Metal Gods has evidently dropped off the face of the earth (for a second time in this RP), and I've decided it's time to find someone else for the role. The band in question is a technical death metal band called Legion, but you can find more about the band itself if you're interested at the RP itself.
Sunday, March 4, 2012
Nebula All-Terrain Vehicle (ATV ) launched in India Features and ...
Nebula All-Terrain Vehicle (ATV ) launched in India Features and Specifications, Review, Price, Image
Nebula Automotive Pvt Ltd, launched a set of all-terrain vehicles in Mumbai today. The company is one of the pioneers in all-terrain vehicles (ATVs) and off-road machines. The firm exhibited 12 such vehicles from 110cc to 800cc power range. These vehicles will be sold in the market through the dealerships established in Pune and Navi Mumbai.
Nebula's ATV vehicles are have a starting price of Rs.90,000 and range up to Rs.15 lakhs. These vehicles can be used for off-road site seeing, beach shore rides, for recreation purposes and also for treading on hard surfaces.
During the launch event, Mr. Sukhdev Asnani, Managing Director of Nebula Automotive Pvt. Ltd. Said that the company has made a move realizing the need for off-road and ATVs in India. Since its early launch, the company has sold over 2000 units of these vehicles. Nebula imports the ATVs in completely knocked down units and assembles in its Pune assembly plant.
Features and Specifications:
Length: 89 inches
Width: 45 inches
Height: 47 inches
Net Weight: 375 kgs.
Gross Weight: 455 kgs.
Engine: 498.6cc ? Water Cooled, 4 Stroke, Single Cylinder
Cylinder Bore Diameter: 92mm (3.63?)
Piston Stroke: 75mm (2.96?)
Compression Ratio: 10.2 : 1
Lubrication: Pressure Splash
Max Power (Kw/rpm): 24Kw (32.2Hp) / 6300rpm
Max Torque: 40Nm / 4800rpm
Ignition: 12V CDI
Start: Electric with a set of keys
Fuel Capacity: 10.5 L
Transmission: CVT Fully Automatic with Hand Reverse, 4 Wheel Drive
Gear Shifting: R,N,D,L (Reverse, Neutral, Drive, Low Gear)
Suspension: Independent Front Suspension with Adjustable Shocks. Heavy Duty Rear Swing Arm with Adjustable Shocks.
Brakes: Front and Rear Disc Brake
Seat Height: Driver : 35? Passenger : 38?
Top Speed: 47 MPH
Top Speed (EEC): 41 MPH
Tyres: (Ft.) 25 x 8-12, (Rr.) 25 x 10-12, (Ft.) 26 x 9-12, (Rr.) 26 x 11-12
Rack Capacity: (Ft.) 35kg., (Rr.) 70kg.
Upgraded Specifications: Winch, Aluminium Rings, Towing Hitch, Wind Screen
EEC 2 UP Extra Configuration: Extra Foot Pad, extra Handle Bar, Extra Seat Back
Tag : Automobile | Mobils | News | Technology | Film | Camera | SMS
More
Source: http://www.allinlives.com/2012/03/nebula-all-terrain-vehicle-atv-launched.html
demi moore roy oswalt kevin martin 2012 senior bowl chuck series finale mitch hedberg welcome back kotter
Saturday, March 3, 2012
Weekending: Art Crawl, Pre-Scientology Pulp Fiction, A Separation ...
Visual Art / Theater / Film Weekending: Art Crawl, Pre-Scientology Pulp Fiction, A Separation
Posted by Steve Haruch on Fri, Mar 2, 2012 at 5:00 AM
The weekend is finally here, and hopefully this afternoon's storms don't ... well, you know. Here are a few things to look forward to after the clouds blow over.* Opening tonight at The Belcourt is pretty much a must-see: A Separation. Here's the opening of Steven Hale's review in this week's Scene:
The first Iranian film to win an Academy Award ? Best Foreign Language Film, in case you missed writer-director Asghar Farhadi's stirring speech Sunday night ? the domestic drama A Separation is a story of dilemmas within dilemmas, of moral, legal, cultural and religious quandaries that only spawn more quandaries, like an infinite set of Russian matryoshka dolls. It will not spoil anything to tell you that A Separation begins and ends with questions for which there is no satisfying answer ? the source of the movie's insight into human nature, as well as its steadily mounting suspense.
* If you Late Shift types want something, uh, slightly less thoughtful: Tim and Eric's Billion Dollar Movie ? a flick that "means to make as many people hold their stomachs as their sides" ? is the midnight feature.
* Saturday brings the Art Crawl, and if you haven't already, you should check Joe Nolan's Crawl Space column for heads-up on what's good.
* Also Saturday, the Church of Scientology Celebrity Center hosts a rather unusual event: a theatrical performance of L. Ron Hubbard's works. Thetans and thespians ? intriguing, for sure.
Subscribe to this thread:
Subscribing?
Showing 1- of
'); } var url = "/gyrobase/blogs/Post"; var myStart = jQuery(this).attr("id") == "sortSelect" ? "1" : jQuery(this).attr("rel"); var showAllComments = jQuery(this).attr("id") == "showAllComments" ? "yes" : "no"; var params = { oid: "2792499", sort: jQuery("#sortSelect").val(), ajaxComponent: componentId, startIndex: myStart, showAll: showAllComments }; jQuery.ajax({ url: url, data: (params), dataType: "html", success: function (data) { jQuery("#"+componentId+"_PaginationBottom").remove(); if (myStart == "1") jQuery("#"+componentId+"_commentContent").html(data); else jQuery("#"+componentId+"_commentContent").append(data); } }); }; function doLikeComment(e){ e.preventDefault(); if (!this.clicked){ var oid = jQuery(this).attr("data-commentOid"); jQuery("#BlogComments #"+oid+"_likeLinks a").addClass("dimmed").css("opacity","0.4").each(function(){this.clicked = true;}); var myCurrentLikes = jQuery("#"+oid+"_rating_likes").html() || 0; var myCurrentDislikes = jQuery("#"+oid+"_rating_dislikes").html() || 0; var thisRating = jQuery(this).attr("rel"); if (thisRating == "Like"){ myCurrentLikes = parseFloat(myCurrentLikes)+1; } else { myCurrentDislikes = parseFloat(myCurrentDislikes)+1; } var myNewLine = '' + myCurrentLikes + ' like'; if (myCurrentLikes != 1) { myNewLine += 's'; } myNewLine += ', ' + '' + myCurrentDislikes + ' dislike'; if (myCurrentDislikes != 1) { myNewLine += "s"; } jQuery("#"+oid+"_rating_sub").html(myNewLine); jQuery("#"+oid+"_rating_sub").show(); var params = { oid: oid, rating: thisRating }; jQuery.ajax({ url: "/gyrobase/Tools/AjaxLike", type: "POST", data: (params), success: function (data) { jQuery("#"+oid+"_rating_sub").html(data); if (thisRating == "Like"){ jQuery("#BlogComments #"+oid+"_likeLinks a.dislike").removeClass("dimmed").css("opacity","1").each(function(){this.clicked = false;}); } else { jQuery("#BlogComments #"+oid+"_likeLinks a.like").removeClass("dimmed").css("opacity","1").each(function(){this.clicked = false;}); } } }); } } function reportComment(e){ e.preventDefault(); e.stopPropagation(); var oid = jQuery(this).attr("rel"); var elem = jQuery("#"+oid+"_report"); elem.click(function(e){e.stopPropagation();}) if (!elem.is(":visible")){ jQuery("#BlogComments .reportCommentContainer").hide(); if (elem.is(":empty")){ var params = { oid: oid, ajaxComponent: "ReportComment" }; jQuery.ajax({ url: "/gyrobase/Tools/ReportComment", data: (params), success: function (data) { elem.html(data); elem.fadeIn("fast"); } }); } else { elem.fadeIn("fast"); } } // attach close event handler to the html jQuery("html").one("click", function(){ jQuery("#BlogComments .reportCommentContainer:visible").hide(); }); } function closeReport(obj){ jQuery(obj).closest(".reportCommentContainer").fadeOut("fast"); } function submitReport(e){ var params = jQuery(e).closest("form").serialize()+"&ajaxComponent=ReportComment"; jQuery.ajax({ url: "/gyrobase/Tools/ReportComment", type: "POST", data: (params), success: function (data) { jQuery(e).closest(".reportCommentContainer").html(data); } }); } (function($) { var subscribed=false; function showFollowPanel(e){ e.preventDefault(); myPanel = $(this).parent().next(".togglePanel"); myPanel.fadeIn("fast"); } function doSubscribe(obj){ var myPanel = obj.parent().next(".togglePanel"); myPanel.fadeIn("fast"); if (!subscribed){ var myLink = obj.parent(); var myLoader = myPanel.children(".loading"); var myUpdater = myPanel.children(".ajaxUpdater"); var params = { object: myPanel.attr("data-toolsoid"), macro: myPanel.attr("data-toolsajaxmacro"), url: window.location }; $.ajax({ url: "/gyrobase/Macros/ToolsAjax", data: (params), type: "POST", dataType: "html", success: function (data) { subscribed = true; if (myUpdater){ myUpdater.html(data); myLoader.fadeOut("fast", function(){ myUpdater.fadeIn("fast", function(){ setTimeout(function(){ myPanel.fadeOut("fast"); }, 3000); }); }); } else { myPanel.fadeOut("fast"); } } }); } } function activateSubscribe(e){ e.preventDefault(); var myObj = $(this); var isAuthenticated = Foundation.SessionManager.sharedSessionManager().isAuthenticated(); if (!isAuthenticated){ new Foundation.Login.Dialog({ "feelingShy": false, "callback": function(){doSubscribe(myObj);} }); return false; } else { // Proceed doSubscribe(myObj); } } $("#BlogComments").on('click', ".bottomOptionBar a#doSubscribe", activateSubscribe); $("#BlogComments").on('click', ".bottomOptionBar a.togglePanelClose", function(){$(this).parent().fadeOut("fast"); return false;}); })(jQuery); jQuery(document).ready(function($){ $("#BlogComments").on('click', '#showMoreComments,#showAllComments', getMoreComments); $("#BlogComments #sortSelect").change(getMoreComments); $("#BlogComments").on('click', 'a.likeLink', doLikeComment); $("#BlogComments").on('click', 'a.reportCommentLink', reportComment); });
topamax lexapro trazodone voting sharon bialek call of duty elite dragonfly
Kroell wins downhill for 2nd straight WCup victory
KVITFJELL, Norway (AP) ? Klaus Kroell of Austria narrowly won a men's World Cup downhill Saturday for his second straight victory on the Olympic course in Kvitfjell.
Kroell shared a super-G victory with Beat Feuz of Switzerland on Friday, but was alone atop the podium after finishing the downhill course in 1 minute, 45.76 seconds.
Kjetil Jansrud was second, 0.02 seconds behind, and fellow Norwegian Aksel Lund Svindal was third, 0.48 behind the winner.
Kroell's sixth career World Cup win moved him to the top of the downhill standings ahead of Swiss veteran Didier Cuche, who finished 10th.
Kroell leads the discipline standings with 569 points, 48 more than Cuche, with two downhill races left at the World Cup finals in Schladming, Austria.
Jansrud, who was bidding for his first World Cup win after eight previous podiums, again lost to Kroell by a slight margin.
In Friday's super-G, the Norwegian finished third when he came in 0.03 behind Kroell and Feuz.
Feuz finished fourth and extended his overall World Cup lead over technical specialist Marcel Hirscher, who is not racing here.
The Swiss skier now has 1,190 points, 55 ahead of Hirscher and 147 ahead of third-place Ivica Kostelic of Croatia.
Kostelic is recovering from knee surgery and is expected to race next weekend's technical events in Kranjska Gora, Slovenia.
Associated Pressderrick mason lamichael james lamichael james harrisburg pa chynna phillips magic cube slaughterhouse
Friday, March 2, 2012
Recreation and Sports: Skateboarding Article Category - velozdh's ...
Recreation and Sports: Skateboarding Article Category
EzineArticles.com allows expert authors in hundreds of niche fields to get massive levels of exposure in exchange for the submission of their quality original articles.Source: http://ezinearticles.com/?cat=Recreation-and-Sports:Skateboarding
Downhill Longboarding Downhill Longboards veloz veloz downhill skate company velozdh
Source: http://velozdh.posterous.com/recreation-and-sports-skateboarding-article-c
nj plane crash plane crash new jersey beef o bradys bowl the hobbit the hobbit an unexpected journey dark knight rises trailer dark knight rises trailer
RIM may warn on BlackBerry shipments, analyst says (Reuters)
[unable to retrieve full-text content]Reuters - Shares of Research In Motion dropped nearly 5 percent on Thursday after an influential analyst said RIM would likely warn that it came up short on BlackBerry shipments this quarter and offer an even bleaker outlook for its flagship smartphone.
robin thicke sacagawea new hope baptist church houston weather associated press foster friess new orleans hornets
Thursday, March 1, 2012
New treatment using inhaled interferon may improve lung function in pulmonary fibrosis
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sq8bHcdgidaHLja0Cwrfz7fMZL2LM3VHMyOe1tr7rRLq3miNbFNA38jCm7V6WGvPiI_eThyo9y6_V_B8h0cRexAZrAnB6OJXlJoASWXSM=s0-d){kind=small}
Public release date: 29-Feb-2012[ | E-mail |
Share ] Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle -- Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article on inhaled interferon-gamma (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919) is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.
Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.
The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled "Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis." (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919)
"There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years," says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. "The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy."
###
About the Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) is an authoritative peer-reviewed journal published bimonthly in print and online. It is the Official Publication of the International Society for Aerosols in Medicine (www.isam.org). The Journal is the only authoritative publication delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. Topics covered include airway reactivity and asthma treatment, inhalation of particles and gases in the respiratory tract, toxic effects of inhaled agents, and aerosols as tools for studying basic physiologic phenomena. Complete tables of content and a sample issue may be viewed on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.
About the Company
Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Pediatric Allergy, Immunology, and Pulmonology, High Altitude Medicine & Biology, and Microbial Drug Resistance. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available online at Mary Ann Liebert, Inc. (http://www.liebertpub.com)
Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: 914-740-2100
800-M-LIEBERT
Fax: 914-740-2101
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 29-Feb-2012[ | E-mail |
Share ] Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle -- Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article on inhaled interferon-gamma (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919) is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.
Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.
The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled "Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis." (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919)
"There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years," says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. "The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy."
###
About the Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) is an authoritative peer-reviewed journal published bimonthly in print and online. It is the Official Publication of the International Society for Aerosols in Medicine (www.isam.org). The Journal is the only authoritative publication delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. Topics covered include airway reactivity and asthma treatment, inhalation of particles and gases in the respiratory tract, toxic effects of inhaled agents, and aerosols as tools for studying basic physiologic phenomena. Complete tables of content and a sample issue may be viewed on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.
About the Company
Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Pediatric Allergy, Immunology, and Pulmonology, High Altitude Medicine & Biology, and Microbial Drug Resistance. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available online at Mary Ann Liebert, Inc. (http://www.liebertpub.com)
Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: 914-740-2100
800-M-LIEBERT
Fax: 914-740-2101
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-02/mali-ntu022912.php
romney michigan railgun jk rowling new book dancing with the stars cast dancing with the stars season 14 usssa baseball mega millions
Subscribe to:
Posts (Atom)